22nd Century Group (XXII) Greatest Growth Milestone, Crown Equity
Post# of 24
Posted On: 10/02/2013 7:34:14 PM
Crown Equity Holdings Inc. (CRWE)
CRWE has refocused its efforts and direction to an online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise.
Strategic plans are also being developed for CRWE’s online video-sharing and VoIP communication projects to improve the potential future growth for the company.
In a recent study of the 2012 VoIP phone system market, Visiongain found that global revenue from VoIP is expected to reach $65 billion this year.
CRWE is targeting that multi-billion dollar market, among others.
Voice over Internet Protocol (VoIP) experienced massive growth at the start of the past five-year period, though residential customer growth has since flattened out. Regulations and the dominance of companies like Google threaten the industry, but the expansion of mobile broadband networks will open up new avenues for growth.
According to GetVoIP, the VoIP market in general should continue to grow since the cost savings VoIP offers over landlines are attracting more customers every day. Until usage grows significantly, though, the VoIP market will likely stay fairly open.
Meanwhile, nearly 80% of businesses are expected to be using VoIP by the end of the year, with 49% already doing so.
CRWE‘s goal is to accelerate the success of the company, by refocusing on prior endeavors to deliver value for its stockholders in both the near and long term.
Together with its digital network of Websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.
*********
22nd Century Group, Inc. (OTCBB:XXII)
XXII reported that its subsidiary, 22nd Century Limited, LLC, and British American Tobacco-(Investments) Limited, a subsidiary of British American Tobacco-plc, have signed a worldwide research license agreement granting BAT access to 22nd Century’s patented technology which alters levels of nicotinic-alkaloids in tobacco-plants.
The Agreement grants British American Tobacco-(Investments) Limited and all other affiliates of British American Tobacco-plc (collectively, “BAT”) rights to three of 22nd Century’s patent families encompassing a cumulative of 28 patents and patent applications in various countries and regions and an option to enter into a worldwide commercial license with 22nd Century.
XXII and its affiliates retain worldwide rights to the technology and patents licensed to BAT for use worldwide in 22nd Century’s products and brands.
The research term of the Agreement is for a period of up to four years during which time 22nd Century and BAT will collaborate on research efforts to further develop the subject technology. Pursuant to the Agreement, BAT can exercise its option to enter into a worldwide royalty-bearing commercial license (the “License”) at any time during the research term.
If the option is exercised, the Agreement would terminate and would be replaced by the License, which would extend to at least the year 2028, unless sooner terminated by either of the parties.
Simultaneous with the signing of the Agreement, BAT is making an upfront payment of $7 million to 22nd Century. Pursuant to the Agreement, BAT is also agreeing to pay to 22nd Century up to an additional $7 million during the course of the research term upon the completion of certain development milestones.
According to XXII, this partnership represents its greatest growth milestone to date and an important step in the development of XXII’s next generation tobacco-products.
XXII is a plant biotechnology company whose proprietary technology allows for the levels of-nicotine and other nicotinic-alkaloids (e.g., nornicotine,-anatabine and-anabasine) in the tobacco-plant to be decreased or increased through genetic engineering or plant breeding.
More about 22nd Century Group, Inc. (OTCBB:XXII) at www.xxiicentury.com
***************************
Read Full Disclaimer at www.bestotc.com/disclaimer
CRWE has refocused its efforts and direction to an online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise.
Strategic plans are also being developed for CRWE’s online video-sharing and VoIP communication projects to improve the potential future growth for the company.
In a recent study of the 2012 VoIP phone system market, Visiongain found that global revenue from VoIP is expected to reach $65 billion this year.
CRWE is targeting that multi-billion dollar market, among others.
Voice over Internet Protocol (VoIP) experienced massive growth at the start of the past five-year period, though residential customer growth has since flattened out. Regulations and the dominance of companies like Google threaten the industry, but the expansion of mobile broadband networks will open up new avenues for growth.
According to GetVoIP, the VoIP market in general should continue to grow since the cost savings VoIP offers over landlines are attracting more customers every day. Until usage grows significantly, though, the VoIP market will likely stay fairly open.
Meanwhile, nearly 80% of businesses are expected to be using VoIP by the end of the year, with 49% already doing so.
CRWE‘s goal is to accelerate the success of the company, by refocusing on prior endeavors to deliver value for its stockholders in both the near and long term.
Together with its digital network of Websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com.
*********
22nd Century Group, Inc. (OTCBB:XXII)
XXII reported that its subsidiary, 22nd Century Limited, LLC, and British American Tobacco-(Investments) Limited, a subsidiary of British American Tobacco-plc, have signed a worldwide research license agreement granting BAT access to 22nd Century’s patented technology which alters levels of nicotinic-alkaloids in tobacco-plants.
The Agreement grants British American Tobacco-(Investments) Limited and all other affiliates of British American Tobacco-plc (collectively, “BAT”) rights to three of 22nd Century’s patent families encompassing a cumulative of 28 patents and patent applications in various countries and regions and an option to enter into a worldwide commercial license with 22nd Century.
XXII and its affiliates retain worldwide rights to the technology and patents licensed to BAT for use worldwide in 22nd Century’s products and brands.
The research term of the Agreement is for a period of up to four years during which time 22nd Century and BAT will collaborate on research efforts to further develop the subject technology. Pursuant to the Agreement, BAT can exercise its option to enter into a worldwide royalty-bearing commercial license (the “License”) at any time during the research term.
If the option is exercised, the Agreement would terminate and would be replaced by the License, which would extend to at least the year 2028, unless sooner terminated by either of the parties.
Simultaneous with the signing of the Agreement, BAT is making an upfront payment of $7 million to 22nd Century. Pursuant to the Agreement, BAT is also agreeing to pay to 22nd Century up to an additional $7 million during the course of the research term upon the completion of certain development milestones.
According to XXII, this partnership represents its greatest growth milestone to date and an important step in the development of XXII’s next generation tobacco-products.
XXII is a plant biotechnology company whose proprietary technology allows for the levels of-nicotine and other nicotinic-alkaloids (e.g., nornicotine,-anatabine and-anabasine) in the tobacco-plant to be decreased or increased through genetic engineering or plant breeding.
More about 22nd Century Group, Inc. (OTCBB:XXII) at www.xxiicentury.com
***************************
Read Full Disclaimer at www.bestotc.com/disclaimer
(0)
(0)